The Calcium Release Activated Calcium Channel Protein 1 pipeline drugs market research report outlays comprehensive information on the Calcium Release Activated Calcium Channel Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Calcium Release Activated Calcium Channel Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Infectious Disease, Oncology, and Respiratory which include the indications Pancreatitis, Ulcerative Colitis, Unspecified Viral Infections, Sepsis, Breast Cancer, Ovarian Cancer, Cystic Fibrosis, and Allergic Asthma. It also reviews key players involved in Calcium Release Activated Calcium Channel Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Calcium Release Activated Calcium Channel Protein 1 pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 5, and 3 respectively.
Calcium Release Activated Calcium Channel Protein 1 overview
Calcium release-activated calcium channel protein 1 (ORAI1) is a protein that plays a crucial role in the regulation of calcium entry into cells, particularly in immune cells. It is an essential component of the calcium release-activated calcium (CRAC) channel, which is a type of calcium channel that is activated when the intracellular calcium stores are depleted.
For a complete picture of Calcium Release Activated Calcium Channel Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
